HOUSTON, TX / ACCESSWIRE / July 27, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company…
Topline data expected in 2024MIAMI, July 27, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”),…
-- Number of subjects increased from 12 to 60 ---- Portable Neuromodulation Stimulator (PoNS®) will be used to evaluate cranial-nerve…
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through…
BRISBANE, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new…
TORONTO, ON / ACCESSWIRE / July 26, 2023 / CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage…
HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced the formation…
BURLINGTON, Mass. and JERUSALEM, July 26, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),…
Constant Therapy Health grants researchers at Boston University and The University of Texas at Austin access to world’s largest speech…
ATH434-201 Trial on Track to Complete Enrollment in Q3 2023 Top-Line Data Expected by the End of 2024 MELBOURNE, Australia…